Skip to main navigation

Patients & Families
Investors
Careers
Follow Us
- X
- LinkedIn
- Glassdoor

Company
Science
Pipeline
- R&D Pipeline
- Clinical Programs
News
- Press Releases

Home
Investors
Events & Publications

Company
Science
Pipeline
- R&D Pipeline
- Clinical Programs
News
- Press Releases

Patients & Families
Investors
Careers
Follow Us
- X
- LinkedIn
- Glassdoor

Search

Reimagining RNA medicine

Menu
Overview
News
Events & Publications
SEC Filings
Stock Information
Analyst Coverage
Corporate Governance
FAQs

Investor Events
Scientific Presentations
Publications

Events & Publications

Year

Positive Interim Phase 1 Clinical Data from INLIGHT Trial of WVE-007 for Obesity

Mar 26, 2026 8:30 AM EDT

Listen to webcast

Presentation 2.3 MB

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026 2:40 PM EST

Listen to webcast

Wave Life Sciences Fourth Quarter 2025 Earnings Call

Feb 26, 2026 8:30 AM EST

Listen to webcast

44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026 5:15 PM EST

Listen to webcast

Wave JPM 2026 Presentation 2.7 MB

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Pagination

Current page 1
Page 2
Page 3
…
Next page
Last page

Investor Inquiries

Kate Rausch

Investor Relations

InvestorRelations@wavelifesci.com

Request information

Email Alerts

Sign up here to receive email alerts from Wave Life Sciences.

Company
Leadership Team
DEI
Corporate Responsibility
Contact Us

Science
PRISM™ Platform
Publications
Collaborations
Manufacturing

Pipeline
R&D Pipeline
Clinical Programs

News
Press Releases

© 2026 Wave Life Sciences. All Rights Reserved.

Privacy
Terms of use
Contact